- Anne Wojcicki, the founder and former CEO of 23andme, agreed to buy a genetic test for $ 305 million. WoJCICKKI will probably provoke lawsuits. The non -profit TTAM Research Institute says it will comply with 23ndme privacy policies.
The rapid and sudden fall-and the new birth-to-birth attempt-the 23ndme Test Test Company has made a final development. A non -profit organization run by Ann Wujiki, co -founder and former CEO of the company, Reach an agreement To buy the company, with a offer of $ 305 million.
The deal, which was announced late on Friday, will witness control of all the assets of the company.
For a long time, back Wojcicki You will not regain control of the company that left it in March. New York -based biotechnology company Regeneron Pharmaceuticals He was appointed to buy 23andme for $ 256 million, but in the final round of bids, the TTAM TTAM Institute came out in WoJCICKI.
The sale of 23ndme, which is once worth $ 6 billion, led to a wave of panic around what It will happen with the genetic data of the customer Hold. Nearly 15 % of its customers, About 1.9 million peopleThey asked to delete their data from the company’s servers since 23andme was submitted for bankruptcy in March. The sale of the company also attracted the interest of the House of Representatives Control Committee, which was concerned about where the data could end.
TTAM says it will consider “privacy policies and law in force” in 23andme, and has provided “binding obligations” to create additional protection and ensure privacy. This consulting council will include the consumer.
23ndme problems came after the company penetrated in 2023, which raised many concerns about the company. For example, one of the online publications that has provided data for sale is proud of the presence of a huge database for Ashkenazi Jews, including people whose relationships with this origin are at the origin of less than 1 %.
WoJCICKI, while she was still the CEO, supervised three rounds of workers ‘demobilization and suggested a plan that would transform the company from a mere supplier of grandparents’ data and to a health care company that develops medicines and sells health reports.
WoJCICKI offered for the first time the company’s purchase in mid -2014. The 23andme Council rejected its attempt to transfer the private company, and later resignation collectively.
The purchase of 23andme is likely to be bought by a group run by wojcicki lawsuits. Earlier this year, an independent investor in 23andme Talk with luck He expressed not believing that wojcicki, who was responsible for allowing 23andme evaluation to collapse, could turn and buy the company at a low price. “I cannot understand why there are no other bids,” I told the investor, who asked to protect his privacy, luck.
This story was originally shown on Fortune.com
https://fortune.com/img-assets/wp-content/uploads/2025/06/GettyImages-2218930663-e1750084956963.jpg?resize=1200,600
Source link